Based on the above mentioned, we propose that aberrant expression of ATAD2 in ESCC could be a new therapeutic target and that aspirin exerts its antitumor activity in ESCC cells by inhibiting the expression of ATAD2 and KIF4A. The gene discussed is KIF4A; the disease is esophageal squamous cell carcinoma.